INM (InMed Pharmaceuticals) Other Stockholders Equity: $-0.00 Mil (As of Mar. 2026)


INM InMed Pharmaceuticals Inc INM
29 GF Score
Price $1.65
GF Value $0.93
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is InMed Pharmaceuticals Other Stockholders Equity?

InMed Pharmaceuticals INM -0.61% 29 Other Stockholders Equity is $-0.00 Mil as of Mar. 2026. GuruFocus rates INM with a GF Score™ of 29/100 and a GF Value™ of $0.93 (Significantly Overvalued). The stock has 4 warning signs investors should review.

InMed Pharmaceuticals's Other Stockholders Equity for the quarter that ended in Mar. 2026 was $-0.00 Mil.

InMed Pharmaceuticals's quarterly Other Stockholders Equity declined from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($-0.00 Mil) and declined from Dec. 2025 ($-0.00 Mil) to Mar. 2026 ($-0.00 Mil).

InMed Pharmaceuticals's annual Other Stockholders Equity declined from Jun. 2023 ($0.00 Mil) to Jun. 2024 ($-0.00 Mil) and declined from Jun. 2024 ($-0.00 Mil) to Jun. 2025 ($-0.00 Mil).

InMed Pharmaceuticals Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for InMed Pharmaceuticals's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InMed Pharmaceuticals Other Stockholders Equity Chart

InMed Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 0.00 0.00 -0.00 -0.00

InMed Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 0.00 -0.00 -0.00
INM
29GF Score
InMed Pharmaceuticals Inc INM
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InMed Pharmaceuticals Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $-0.00 Mil mean?
InMed Pharmaceuticals (INM) has a Other Stockholders Equity of $-0.00 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on InMed Pharmaceuticals and its competitors.
Is InMed Pharmaceuticals' Other Stockholders Equity too high?
InMed Pharmaceuticals' current Other Stockholders Equity is $-0.00 Mil. Overall, InMed Pharmaceuticals has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does InMed Pharmaceuticals' Other Stockholders Equity compare to SNOA and CVSI?
InMed Pharmaceuticals' Other Stockholders Equity of $-0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on InMed Pharmaceuticals and its competitors. InMed Pharmaceuticals's current Other Stockholders Equity is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InMed Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, InMed Pharmaceuticals (INM) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.93, compared to a current price of $1.65 — trading 77.4% above its estimated fair value. The current Other Stockholders Equity is $-0.00 Mil. InMed Pharmaceuticals' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For InMed Pharmaceuticals (INM), the current Other Stockholders Equity is $-0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InMed Pharmaceuticals (INM) Overvalued in 2026?

Based on GuruFocus' analysis, InMed Pharmaceuticals stock appears to be overvalued. The current stock price of $1.65 is trading 77.4% above its estimated GF Value™ of $0.93. GuruFocus considers InMed Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for INM:

  • Other Stockholders Equity: $-0.00 Mil
  • GF Value™: $0.93 vs. price of $1.65 (77.4% above fair value)
  • GF Score™: 29/100 with 4 warning signs

No single metric tells the full story. See the INM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InMed Pharmaceuticals Business Description

Other Exchanges MWG:Germany
Address 885 West Georgia Street, Suite 1445, Vancouver, BC, CAN, V6C 3E8
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
29GF Score

Get the complete analysis for INM

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.65
Price
$0.93
GF Value